Regulation of prolactin secretion by adrenal steroids in oestrogen-treated ovariectomized rats: participation of endogenous opioid peptides.
The purpose of the present study was to determine whether glucocorticoid inhibition of prolactin (PRL) release in oestrogen-treated ovariectomized (OVX) rats is mediated by endogenous opioid peptides (EOPs). All the animals were OVX and given oestradiol benzoate (OB, 20 microg/rat, s.c.) 2 weeks later (day 0). On day 3 they received vehicle, mifepristone (MIF, 10 mg/kg, s.c.) or hydrocortisone (HYD, 2 mg/rat, s.c.), in combination with the opioid antagonist naloxone (NAL, 2 mg/kg, i.p.) or vehicle. Serum PRL concentration was then measured by RIA at 13.00 and 18.00 hr, to include assessment of diurnal variation of PRL secretion. At 13.00 hr either MIF or NAL alone increased PRL secretion with no additional effect when NAL was combined with MIF. HYD had no significant inhibitory effect, but NAL with HYD increased PRL secretion. At 18.00 hr serum PRL concentration was higher than at 13.00 hr, and not affected significantly by MIF or NAL alone, although PRL secretion was increased by treatment with both. HYD inhibited PRL secretion and this inhibition was prevented by NAL. In a second experiment to distinguish antiglucocorticoid and antiprogesterone effects of MIF, we administered progesterone (2 mg/rat, s.c.) or a specific progesterone antiserum. In contrast with MIF, the progesterone antibody had no effect on PRL secretion at 13.00 hr, nor on the stimulation by NAL, while progesterone (unlike HYD) increased PRL secretion and NAL attenuated this response; this was opposite to the effect of NAL with HYD. Similarly, at 18.00 hr the interaction of MIF and NAL was not explained by antagonism of progesterone. Together, these results indicate inhibition of PRL by glucocorticoids but not progesterone, mediated in part by EOPs. At 18.00 hr endogenous glucocorticoids do not regulate oestrogen-stimulated PRL release, although HYD is inhibitory through EOPs.
Carón
R W
RW
Laboratorio de Reproducción y Lactancia, LARLAC-CONICET, Mendoza, Argentina.
Salicioni
A M
AM
Deis
R P
RP
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology; D006854:Hydrocortisone / Q000494:pharmacology; D015735:Mifepristone / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D018847:Opioid Peptides / Q000378:metabolism*; D010052:Ovariectomy; D011374:Progesterone / Q000276:immunology / Q000494:pharmacology; D011388:Prolactin / Q000097:blood / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar / Q000601:surgery
D000893:Anti-Inflammatory Agents; D006727:Hormone Antagonists; D018847:Opioid Peptides; D015735:Mifepristone; D009270:Naloxone; D011374:Progesterone; D004958:Estradiol; D011388:Prolactin; D006854:Hydrocortisone